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Background. Co-infection with hepatitis C in HIV-infected individuals is associated with 3- to 4-fold higher mortality among
these patients’ siblings, compared with siblings of mono-infected HIV-patients or population controls. This indicates that risk
factors shared by family members partially account for the excess mortality of HIV/HCV-co-infected patients. We aimed to
explore the causes of death contributing to the excess sibling mortality. Methodology and Principal Findings. We retrieved
causes of death from the Danish National Registry of Deaths and estimated cause-specific excess mortality rates (EMR) for
siblings of HIV/HCV-co-infected individuals (n=436) and siblings of HIV mono-infected individuals (n=1837) compared with
siblings of population controls (n=281,221). Siblings of HIV/HCV-co-infected individuals had an all-cause EMR of 3.03 (95% CI,
1.56–4.50) per 1,000 person-years, compared with siblings of matched population controls. Substance abuse-related deaths
contributed most to the elevated mortality among siblings [EMR=2.25 (1.09–3.40)] followed by unnatural deaths [EMR=0.67
(20.05–1.39)]. No siblings of HIV/HCV co-infected patients had a liver-related diagnosis as underlying cause of death. Siblings
of HIV-mono-infected individuals had an all-cause EMR of 0.60 (0.16–1.05) compared with siblings of controls. This modest
excess mortality was due to deaths from an unknown cause [EMR=0.28 (0.07–0.48)], deaths from substance abuse [EMR=0.19
(20.04–0.43)], and unnatural deaths [EMR=0.18 (20.06–0.42)]. Conclusions. HCV co-infection among HIV-infected patients
was a strong marker for family-related mortality due to substance abuse and other unnatural causes. To reduce morbidity and
mortality in HIV/HCV-co-infected patients, the advances in antiviral treatment of HCV should be accompanied by continued
focus on interventions targeted at substance abuse-related risk factors.
Citation: Hansen A-BE, Lohse N, Gerstoft J, Kronborg G, Laursen A, et al (2007) Cause-Specific Excess Mortality in Siblings of Patients Co-Infected with
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INTRODUCTION
Co-infection with HCV is a marker for poor prognosis in HIV-
infected individuals. It is unclear whether the prognostic impact is
caused directly by the viral disease, or whether it is an
epiphenomenon of the infection [1–3]. It has been suggested that
HCV exerts a direct pathogenic effect by compromising the
immune restoration induced by highly active antiretroviral therapy
(HAART) [1,4,5], but it has been difficult to separate the direct
pathogenic effects of HCV from indirect effects of associated risk
factors. In most settings, HCV infection is closely linked with
intravenous drug use (IDU), which is associated with risk factors
such as mental health illnesses, depression and alcohol abuse [6,7].
In a recent attempt to uncover the impact of the indirect effects,
we examined the mortality in siblings of HIV/HCV-co-infected
individuals. We found three- to four-fold higher mortality among
siblings of HCV/HIV-co-infected patients, compared to siblings of
HIV-mono-infected individuals and siblings of population controls
[8]. This indicates that risk factors shared by family members
partially account for the excess mortality of HIV/HCV-co-
infected patients. Given the high parenteral transmissibility of
HCV, we hypothesized that HCV infection is a marker of high-
risk lifestyle associated with intravenous drug use (IDU). However,
the excess mortality could also be mediated through shared
susceptibility to some infectious pathogens or increased prevalence
of HCV infection among siblings of HIV/HCV-co-infected
individuals.
To explore the excess mortality shared among family members,
we used a nationwide population-based Danish cohort to compare
cause-specific mortality rates, including mortality associated with
drug and alcohol abuse, among three groups: siblings of HIV/
HCV-co-infected individuals, siblings of HIV-mono-infected
individuals, and siblings of general population controls.
METHODS
The study setting and methods used to identify siblings have been
described in detail previously [8]. Briefly, we used the population-
based Danish HIV Cohort Study (DHCS) [9] to identify all
Danish HIV mono-infected and HIV/HCV co-infected patients
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Denmark is restricted to eight specialised centres, and the Danish
health care system provides free tax-supported medical care,
including antiretroviral treatment for HIV.
We identified up to 99 population controls per patient, matched
by gender, age and residency from the Danish Civil Registration
System (CRS). CRS is an electronic database established in 1968,
which tracks vital status, migration, residency and kinship for all
Danish inhabitants [10]. CRS records contain a unique 10-digit
civil registration number that allows accurate record linkage with
other registries. For both HIV-infected patients and population
controls, we identified all full siblings born after 1951 (as
registration of kinship was incomplete before this date) and
obtained their dates of death or emigration from CRS. Based on
the HIV patients’ HCV serostatus or tests for HCV-RNA, siblings
of HIV-infected individuals were classified as siblings of HIV-
mono-infected individuals or siblings of HIV/HCV-co-infected
individuals [8]. A flowchart of eligible individuals is displayed in
Figure 1.
We used the National Registry of Deaths (NRD) [11] to
document causes of death for the three sibling groups. The NRD
contains information from all Danish death certificates since 1943,
coded according to the Danish version of International Classifi-
cation of Diseases [ICD-8 from 1972 through 1993, and ICD-10
from 1994 through 2001].
We followed the siblings from age 20 until death, emigration, or
their 50
th birthday, whichever came first. All subjects were censored
after 31 December 2001, the latest date when electronically coded
causes of death were available in the NRD. In the current study, the
number of siblings, person years of follow-up, and number of deaths
were slightly smaller than in our earlier study of mortality among
siblings of HCV/HIV-co-infected patients, in which follow up was
censored on 1 May 2005 [8]. Figure 1 displays a summary of the
study design for selection of siblings.
We classified causes of death into five groups, based on death
certificate information:
1. Alcohol or drug abuse-related;
2. HIV (excluding those related to substance abuse);
3. Natural causes (excluding those related to HIV or substance
abuse);
4. Unnatural causes (including deaths due to accidents, suicide,
or homicide and excluding deaths related to substance
abuse);
5. Unknown causes.
To capture deaths related to abuse of alcohol and drugs
(including some prescription drugs), we used diagnoses for both the
underlying (main) and contributory causes of death. The causes of
death defined as substance-abuse related were: a) mental disorders
associated with alcohol or drug dependence (ICD-8: 291, 303, or
304. ICD-10: F10-F19); b) toxic effect of/poisoning by alcohol
(ICD-8: E860, N979, or N980. ICD-10: X45, T51, or Y15); c)
non-mental diseases caused by alcohol (ICD-8: 5710, 5711, or
5771. ICD-10: G312, G621, G721, I426, K292, K70, or K860);
and d) toxic effect of/poisoning by specified psychoactive drugs
Figure 1. Summary of the study design. CRS, the Danish Civil Registration System; HCV, Hepatitis C virus. * Number of siblings in [8]
doi:10.1371/journal.pone.0000738.g001
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purposely inflicted] (ICD-8: E8530, E8540, or, E950 or E980 in
combination with N9650, N9780, or N9790. ICD-10: X41, X42,
or X60-X64 in combination with T40, Y11, Y12) [12]. For all
other causes (group 2-5), only the underlying cause of death was
used. In the Danish versions of ICD-8 and ICD-10, deaths with
HIV as the underlying cause are coded as 0797 and B20-B24,
respectively.
Among individuals with HIV as the underlying cause of death,
the route of infection was identified from DHCS records. Deaths
in those who were intravenous drug users were reclassified as
a IDU-related death in a supplementary analysis, as proposed by
Schulz-Schaeffer et al. [13]. We also performed a supplementary
analysis of deaths with HCV infection or other liver diseases as the
underlying cause of death.
For the three groups of siblings, we first computed total and
cause-specific mortality rates (MR) by person-year analyses and
used exact poisson confidence intervals. We then calculated total
and cause-specific absolute excess mortality rates (EMR), com-
paring siblings of HIV-mono-infected and HIV/HCV-co-infected
patients with siblings of population controls (the reference group).
We calculated absolute EMR as the risk difference between two
groups as described by Rothman [14] i.e. by subtracting the MR
of siblings of population controls from the MR for siblings of each
of the other two groups. We calculated 95% confidence intervals
for the EMRs by using the standard error of the rate difference as
described by Rothman [14,15]. We used Stata software, version
9.2 (StataCorp, College Station, TX, USA) for statistical analyses.
The study was approved by the Danish Data Protection Agency.
RESULTS
Patients, population controls and their siblings
As of 1 May 2005, DHCS included 4,261 Danish residents who
were older than 16 years at the time of HIV diagnosis. We
excluded 271 patients not living in Denmark at time of HIV
diagnosis and 459 patients who were never tested for HCV. Of the
remaining 3,531 patients, 673 had HIV/HCV co-infection and
2858 were HIV-mono-infected. Owing to an insufficient number
of eligible controls in some municipalities, the study included
a mean of 95.3 population controls per HIV patient, yielding
336,652 matched controls. The HIV/HCV co-infected patients
had 436 siblings, the HIV mono-infected patients had 1,837
siblings, and the population controls had 281,221 siblings. Nine
families included two siblings with HIV. Hence, 18 persons were
included as both HIV patients and siblings of HIV patients.
Mortality rates of siblings
The 436 siblings of HIV/HCV-co-infected individuals contributed
7,199 person-years of follow-up (PYR), followed from age 20
years. During this time we observed 29 deaths [MR=4.03 per
1,000 PYR] (Table 1). Eighteen deaths were substance abuse-
related [MR=2.50 per 1,000 PYR]. The 1,837 siblings of HIV-
mono-infected individuals contributed 31,232 PYR and 50 deaths
[MR=1.60 per 1,000 PYR], with 14 deaths [MR=0.45 per 1,000
PYR] attributable to substance abuse. Finally, the 281,221 siblings
of population controls contributed 4,590,754 PYR and 4,588
deaths [MR=1.00 per 1,000 PYR], of which 1,169 deaths [MR
0.25 per 1,000 PYR] were substance abuse-related.
Excess mortality rates of siblings
Total and cause-specific MR and EMR with 95% confidence
intervals for all groups of siblings are displayed in Table 1. The all-
cause EMR for siblings of HIV/HCV-co-infected individuals was
3.03 per 1,000 PYR, compared with siblings of population
controls. This excess mortality was mainly caused by substance
abuse-related deaths (EMR=2.25 per 1000 PYR) and to a lesser
extent by unnatural deaths (EMR=0.67 per 1,000 PYR) and by




This small excess mortality was due to deaths from an unknown
cause (EMR=0.28 per 1,000 PYR), deaths from substance abuse
(EMR=0.19 per 1,000 PYR), and unnatural deaths (EMR=0.18
per 1,000 PYR).
Substance abuse in HIV-related deaths
Three siblings of HIV/HCV-co-infected individuals and 137
control siblings had HIV as their underlying cause of death. Of
these, two siblings of HIV/HCV-co-infected individuals and four
control siblings were registered in DHCS with IDU as the route of
HIV transmission. When these deaths were counted as substance
abuse-related deaths, the cause-specific mortality rate for siblings
of HIV/HCV-co-infected individuals increased from 2.50 to 2.78
per 1,000 PYR, and the EMR increased from 2.25 to 2.52 per
1,000 PYR. The substance abuse-related mortality rate for
controls changed slightly from 0.25 to 0.26 per 1,000 PYR.
HCV-related deaths
No siblings of HIV/HCV-co-infected patients had acute or
chronic HCV infection or any other liver-related diagnosis as
the underlying cause of death.
DISCUSSION
Our nationwide study showed that the increased mortality in
siblings of HIV/HCV-co-infected patients is mainly caused by
alcohol and drug abuse-related deaths. The study did not provide
evidence that hepatitis C infection or increased inherited
susceptibility to other infectious diseases contribute to the excess
mortality in siblings of HIV/HCV co-infected patients.
These results lend credence to the hypothesis that excess
mortality in HIV/HCV-co-infected patients, compared to HIV
mono-infected patients, partly stems from factors other than the
HCV disease itself, and a large part of the increased mortality in
HIV/HCV co-infected patients - compared to HIV mono-infected
patients - may be caused by similar family-associated and lifestyle-
related factors. In the co-infected patients, substance abuse and
associated risk behaviors may directly affect mortality. Indirectly,
mortality in HIV/HCV-co-infected patients may be elevated by
suboptimal health-seeking behavior, poor adherence to medical
treatment, drug- or alcohol-related comorbidity, or health care
providers’ inattention to these patients. In addition, clinicians may
choose to postpone antiretroviral therapy in HIV/HCV-co-
infected patients due to concerns about behavioral factors or liver
toxicity, despite evidence that early treatment initiation is
beneficial for these patients [16].
The mechanisms underlying clustering of substance abuse-
related deaths in families of HIV/HCV-co-infected individuals
require better understanding. A likely explanation is that the
common childhood and environment among siblings lead to
a similar high risk of substance abuse. However, adoption and twin
studies have shown that in addition to family environment, there is
a strong genetic contribution to a familial predisposition for
substance abuse [17,18]. In any case, familial clustering of the
detrimental effects of substance abuse underscores the need for
HIV/HCV and Death of Siblings
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when effects of HCV are investigated in epidemiological settings.
Further evaluation is also needed to determine whether these
family-related risk factors have the same influence on prognosis in
HCV-mono-infected patients, because HIV/HCV-co-infected
individuals may represent a more vulnerable subgroup than
HCV-mono-infected individuals. In line with our results, a large
population-based study has recently demonstrated that young
people with HCV infection have higher mortality from continued
drug uses than from the HCV infection [19].
Our study had a number of strengths and limitations. Use of
longitudinal population-based Danish registries permitted com-
plete long-term follow-up with minimal selection bias, while the
matched selection of siblings assured comparability of groups in
terms of birth year and residency [8]. Because it has been shown
that relying exclusively on underlying cause of death leads to
underestimation of alcohol- and drug-related mortality, we used
both underlying and contributory causes [12,13] to specify these
causes of death. Still, death certificate data are not entirely
accurate [20], and potential differential misclassification could lead
to underestimation of the contribution of substance abuse to the
category of unnatural deaths [13,21]. We could not assess mode of
HIV infection in all HIV-related deaths among siblings of
population controls. However, the resulting bias is probably
negligible, since both the MR of HIV-related deaths and the
proportion of HIV infections acquired by IDU among those with
HIV-related deaths were small in this group. Finally, it is
important to note that the results of this study may not be
generalizable to settings where HIV/HCV-co-infected patients do
not have IDU as the main route of transmission, for example
Africa [22].
In conclusion, HCV co-infection among HIV-infected patients
seemed to be a strong marker for family-related mortality due to
substance abuse. In order to reduce morbidity and mortality in
HIV/HCV co-infected patients, advances in antiviral treatment of
HCV should be accompanied by interventions targeted at
substance abuse and associated risk factors.
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Table 1. Total and cause-specific MR and excess MR among the three groups of siblings.
..................................................................................................................................................
Causes of deaths in sibling
groups Number of deaths Person-years MR per 1000 PY (95% CI) Excess mortality rates (95% CI)
Total
Control 4588 4,590,754 1.00 (0.97–1.03)
HIV 50 31,232 1.60 (1.19–2.11) 0.60 (0.16–1.05)
HIV/HCV 29 7,199 4.03 (2.70–5.79) 3.03 (1.56–4.50)
Substance abuse
Control 1169 4,590,754 0.25 (0.24–0.27)
HIV 14 31,232 0.45 (0.25–0.75) 0.19 (20.04–0.43)
HIV/HCV 18 7,199 2.50 (1.48–3.95) 2.25 (1.09–3.40)
Unnatural causes
Control 1,381* 4,590,754 0.30 (0.29–0.32)
HIV 15** 31,232 0.48 (0.27–0.79) 0.18 (20.06–0.42)
HIV/HCV 7*** 7,199 0.97 (0.39–2.00) 0.67 (20.05–1.39)
HIV
Control 137 4,590,754 0.03 (0.03–0.04)
HIV 2 31,232 0.06 (0.01–0.23) 0.03 (20.05–0.12)
HIV/HCV 3 7,199 0.42 (0.09–1.22) 0.39 (20.08–0.86)
Natural causes
Control 1,547 4,590,754 0.34 (0.32–0.35)
HIV 8 31,232 0.26 (0.11–0.50) 20.08 (20.26–0.10)
HIV/HCV 1 7,199 0.14 (0.00–0.77) 20.20 (20.47–0.07)
Unknown mode/cause of death
Control 354 4,590,754 0.08 (0.07–0.09)
HIV 11 31,232 0.35 (0.18–0.63) 0.28 (0.07–0.48)
HIV/HCV 0 7,199 0 { 20.08{
*649 accidents, 618 suicides, 69 homicides, 45 injuries undetermined whether accidentally or purposely inflicted
**6 suicides, 9 accidents,
***3 suicides, 3 accidents, 1 injury undetermined whether accidentally or purposely inflicted
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